Bellerophon Therapeutics inc (BLPH) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access BLPH Annual Balance Sheets →
This balance sheet overview for Bellerophon Therapeutics inc spans from Sep 30 2022 to Sep 30 2023, showing how the company's assets, liabilities, and equity have evolved across reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Assets
Cash & cash equivalent4.38
Restricted Cash and Cash Equivalents, Current0.11
Cash & Short-term Investments4.00
Other Current Assets0.00
Prepaid Expense And Other Assets Current0.49
Total Current Assets4.98
Equipment/Property/Plant Net0.00
Other Assets, Noncurrent0.00
Operating Lease Right Of Use Asset-
Total Assets4.98
Liabilities
Accounts Payable, Trade, Current0.61
Other Accrued Liabilities, Current0.31
Other Liabilities, Current0.00
Total Current Liabilities1.26
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
OperatingLeaseLiabilityCurrent-
Accrued Research And Development0.34
Total Liabilities1.26
Stockholders' Equity
Common Stock Value0.12
Additional Paid In Capital Common Stock259.92
Retained Earnings / Accumulated Deficit-256.32
Defined Benefit Plan and Other0.00
Other Equity0.00
Common Stockholder's Equity3.72
Total Stockholder's Equity3.72
Liabilities & Stockholder's Equity4.98
4 historic quarters locked

Sign in to unlock the full Bellerophon Therapeutics inc balance sheet history.

About Bellerophon Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001558370-23-019044

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.